Artelo Biosciences Inc (NASDAQ:ARTL) experienced a sharp increase in its share price after the firm confirmed a study agreement with the Belfast Health and Social Care Trust to evaluate ART27.13 in patients with glaucoma or ocular hypertension. The announcement was followed by a substantial intraday move in the company stock.
The upcoming investigation is an investigator-initiated clinical study that will examine the safety and potential intraocular pressure effects of ART27.13, a peripherally selective synthetic cannabinoid. Funding for the trial will be provided by Glaucoma UK and the HSC R&D Division. The study team anticipates beginning enrollment of the first patient in the second quarter of 2026.
Glaucoma is a major global cause of irreversible vision loss, affecting more than 80 million individuals worldwide. Elevated intraocular pressure is identified in the study materials as the primary modifiable risk factor for progression of the disease. The materials further note that current treatment options can be constrained by patient adherence and tolerability issues.
ART27.13 is described as a compound intended to modulate intraocular pressure through activation of cannabinoid receptors located in peripheral tissues, including ocular tissues. Its peripherally selective profile is intended to minimize central nervous system effects that have limited the wider use of other cannabinoids for intraocular pressure management.
The Northern Ireland Clinical Trials Unit will conduct the study under the leadership of Professor Augusto Azuara-Blanco, Clinical Professor of Ophthalmology at Queen's University Belfast. According to the agreement, the study protocol has received approval from the ethics committee and the Medicines and Healthcare products Regulatory Agency.
Under the terms of the agreement, Artelo will supply ART27.13 in capsule form for oral administration in the trial. Company materials state that this collaboration expands the clinical exploration of ART27.13 beyond its lead development focus on cancer-related anorexia.
Greg D. Gorgas, President and Chief Executive Officer of Artelo Biosciences, characterized the collaboration as a capital-efficient development approach that leverages investigator-initiated research to broaden the potential applications of the company's compounds.
Study and operational details
- The trial is investigator-initiated and will be run by the Northern Ireland Clinical Trials Unit.
- Professor Augusto Azuara-Blanco will lead the study; ethical and regulatory approvals are in place.
- Funding will be supplied by Glaucoma UK and the HSC R&D Division, with first patient enrollment expected in Q2 2026.
Clinical rationale
The study aims to assess whether ART27.13 can influence intraocular pressure via peripheral cannabinoid receptor activation while avoiding central nervous system exposure. This design targets a known limitation of prior cannabinoid-based approaches to intraocular pressure modulation.
Context for investors and markets
For investors, the agreement represents an additional clinical pathway that could broaden ART27.13's potential indications beyond cancer-related anorexia. The arrangement also reflects a strategy of partnering with investigator-initiated efforts to advance clinical data without fully internalizing the costs of early-stage trials.